113 related articles for article (PubMed ID: 15848517)
1. Conversion of azathioprine to mycophenolate mofetil and chronic graft failure progression.
Lezaic VD; Marinkovic J; Ristic S; Dokic ZM; Basta Jovanovic G; Radivojevic DM; Blagojevic RN; Djukanovic LD
Transplant Proc; 2005 Mar; 37(2):734-6. PubMed ID: 15848517
[TBL] [Abstract][Full Text] [Related]
2. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
Lou HX; Vathsala A
Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation.
Wüthrich RP; Cicvara S; Ambühl PM; Binswanger U
Nephrol Dial Transplant; 2000 Aug; 15(8):1228-31. PubMed ID: 10910450
[TBL] [Abstract][Full Text] [Related]
6. Effect of mycophenolate mofetil on kidney graft function and body weight in patients with chronic allograft nephropathy.
Grebe SO; Mueller TF; Troeltsch M; Ebel H; Lange H
Transplant Proc; 2004 Dec; 36(10):2974-8. PubMed ID: 15686673
[TBL] [Abstract][Full Text] [Related]
7. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
[TBL] [Abstract][Full Text] [Related]
9. Conversion from mycophenolate mofetil to azathioprine in renal allograft [corrected] patients within the first month posttransplantation.
Zhu B; Liu Z; Wu C; Wang P; Wang X; Xu H
Transplant Proc; 2008 Sep; 40(7):2258-61. PubMed ID: 18790207
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
12. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.
Merion RM; Henry ML; Melzer JS; Sollinger HW; Sutherland DE; Taylor RJ
Transplantation; 2000 Jul; 70(1):105-11. PubMed ID: 10919583
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
14. Randomised open clinical trial of conversion from mycophenolate mofetil to azathioprine in cadaveric renal transplantation.
Nowacka-Cieciura E; Kamiñska B; Cieciura T; Gradowska L; Pazik J; Lao M; Rowiñski W; Paczek L
Transpl Int; 2000; 13 Suppl 1():S68-72. PubMed ID: 11111965
[TBL] [Abstract][Full Text] [Related]
15. Conversion from azathioprine to mycophenolate mofetil followed by calcineurin inhibitor minimization or elimination in patients with chronic allograft dysfunction.
Garcia R; Pinheiro-Machado PG; Felipe CR; Park SI; Silva LA; Franco MF; Tedesco-Silva H; Medina-Pestana JO
Transplant Proc; 2006 Nov; 38(9):2872-8. PubMed ID: 17112853
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy.
Gonzalez Molina M; Seron D; Garcia del Moral R; Carrera M; Sola E; Jesus Alferez M; Gomez Ullate P; Capdevila L; Gentil MA
Transplantation; 2004 Jan; 77(2):215-20. PubMed ID: 14742984
[TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Attallah N; Goggins M; Nori U; Abouljoud M; Zasuwa G; Venkat KK; Parasuraman R
Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
[TBL] [Abstract][Full Text] [Related]
18. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
[TBL] [Abstract][Full Text] [Related]
19. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients.
Khosroshahi HT; Asghari A; Estakhr R; Baiaz B; Ardalan MR; Shoja MM
Transplant Proc; 2006 Sep; 38(7):2077-9. PubMed ID: 16980004
[TBL] [Abstract][Full Text] [Related]
20. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
